Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Perimeter appoints finance executive Michelle Caron to BOD

Perimeter Medical Imaging AI (TSX-V: PINK; OTCQX: PYNKF) has announced that Michelle Caron, CPA, has been appointed to its board of directors (BOD), effective immediately. In a finance career spanning more than 28...

October 2, 2026

Executive Moves

Lynn Chapman joins AI/ML as CFO

AI/ML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has appointed Lynn Chapman, CPA, CA, as chief financial officer (CFO), effective October 1, 2026. Mr. Chapman brings more than 15 years of financial and managerial...

October 2, 2026

Developments

FDA clears IND application for Surrozen’s SZN-8141 in DME

Surrozen (NASDAQ: SRZN) has announced its Investigational New Drug (IND) application for SZN-8141 for the treatment of diabetic macular edema (DME) has become effective, enabling advancement to clinical development. SZN...

October 2, 2026

Developments

Tenon launches titanium 3D-printed lateral screw

Tenon Medical (NASDAQ: TNON) has announced the full commercial launch of its new titanium 3D-printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the...

September 30, 2026

Developments

Connect reports positive data from study of rademikibart in COPD

Connect Biopharma (NASDAQ: CNTB) has announced topline results from its global Phase 2 study evaluating rademikibart, its next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody as...

September 30, 2026

Developments

Valion sees potential for multi-fold expansion of long-term opportunity after successful joint formulation of oral mucosal Entolimod for acute radiation syndrome

Valion Bio (NASDAQ: VBIO) and closely held Shear Kershman Laboratories (SKL) announced the successful completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of...

September 30, 2026

Developments

Immix reports 89% CR in trial of NXC-201 in R/R AL amyloidosis

Immix Biopharma (NASDAQ: IMMX) has reported interim data showing an 89% complete response (CR) rate across all 45 enrolled patients, based on an assessment by an independent review committee, from its NEXICART-2 Phase 2...

September 29, 2026

Executive Moves

Robert DiTota joins Nexalin as senior strategic advisor

Nexalin Technology (NASDAQ: NXL) has announced the appointment of Robert DiTota as senior strategic advisor, global commercialization, effective September 15, 2026. Mr. DiTota brings more than 20 years of neuroscience...

September 29, 2026

Markets

Clear Street starts Q32 Bio at buy; PT $38

Clear Street initiated coverage of Q32 Bio (NASDAQ: QTTB) with a “buy” rating and price target of $38.00. The stock closed at $8.77 on September 25. Q32 Bio is a clinical-stage biotechnology company developing therapies...

September 28, 2026

Markets

Lucid starts Lensar at buy; PT $11

Lucid Capital Markets initiated coverage of Lensar (NASDAQ: LNSR) with a “buy” rating and price target of $11.00. The stock closed at $6.92 on September 25. Lensar designs, manufactures, and commercializes femtosecond...

September 28, 2026

Developments

Codexis enters agreement with drug innovator to create stereo-defined siRNA

Codexis (NASDAQ: CDXS) has announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. According to Codexis, the agreement...

September 28, 2026

Developments

DataMeds AI and Tollo Health announce mobile app

DataMeds AI (NASDAQ: MEDS) and closely held Tollo Health have announced the launch of the Health Lives Here mobile application (app), initially focused on supporting users of GLP-1 receptor agonist medications...

September 28, 2026

Subscribe